Turmeric for Functional Dyspepsia and Bloating

Table of Contents

1. What Functional Dyspepsia Actually Is
2. Why It Happens — Four Overlapping Faults
3. The 1989 Thai Trial
4. The 2023 Trial Against Omeprazole
5. Why Poor Absorption Matters Less Here
6. Breath Hydrogen: Measuring Gas Objectively
7. Gastric Emptying — The Mouse Evidence
8. How People Actually Take It
9. The Honest Limits of This Evidence
10. When to See a Doctor Instead
11. Key Research Papers
12. Connections
13. Featured Videos

What Functional Dyspepsia Actually Is

"Functional" is a word that has done a lot of damage to a lot of patients. It does not mean imaginary, psychosomatic, or trivial. In gastroenterology it means a disorder of how the gut works rather than of how it is built — the plumbing is intact, the wiring is misbehaving. A cardiologist would say the same of an arrhythmia in a structurally normal heart, and nobody tells those patients it is in their head.

Functional dyspepsia is defined by persistent symptoms centred on the upper abdomen, in the absence of any structural disease that explains them. The formal criteria — the Rome criteria, revised periodically by international consensus — split it into two overlapping subtypes, and the split is genuinely useful because they respond to different things:

1. Postprandial distress syndrome (PDS). Bothersome fullness after ordinary meals, and early satiety — you fill up after a few mouthfuls. Bloating and belching cluster here. This is the meal-related subtype, and it is the one that most resembles what a Thai pharmacy label means by "wind and distension".
2. Epigastric pain syndrome (EPS). Pain or burning in the upper middle abdomen, not necessarily tied to eating. This subtype shades towards what people call heartburn, though reflux is a separate diagnosis.

Plenty of people have both. A comprehensive 2026 review of the pathophysiology, epidemiology and international management guidelines sets out how the definitions have evolved and how variably the condition is treated across health systems — worth knowing, because it explains why two doctors can give you two entirely different plans for the same symptoms.

The condition is common, it is chronic, and it relapses. Estimates of how many adults have it vary widely depending on which criteria a study uses and which country it surveys, which is itself part of the story: this is a condition defined by symptoms, and symptom definitions move. What does not move is the clinical reality — a large number of people feel persistently unwell after eating and have been told there is nothing to find.

Back to Table of Contents

Why It Happens — Four Overlapping Faults

No single mechanism explains functional dyspepsia. Four keep appearing, and most patients have some mixture.

Impaired accommodation

A healthy stomach relaxes as food arrives, like a balloon slackening so that it can take more air at the same pressure. This reflex is called accommodation. When it fails, the stomach stays stiff, pressure rises with a normal volume of food, and stretch receptors report a full stomach after a small meal. That is early satiety, and it is a mechanical failure, not an attitude problem.

Delayed gastric emptying

In a substantial minority, the stomach empties more slowly than it should. Food sits. Fermentation gets longer to happen. The sense of heaviness has an obvious physical basis.

Visceral hypersensitivity

The nerves reporting from the gut are turned up too loud. Normal distension, normal acid, normal peristalsis get reported to the brain as discomfort. This is why some people with completely normal emptying still hurt, and why drugs that suppress acid often fail — the acid was never abnormal, the reporting was.

Low-grade mucosal inflammation and barrier changes

The newest strand. Studies have found modest increases in immune cells — particularly eosinophils and mast cells — in the duodenum of people with functional dyspepsia, along with subtle changes in the intestinal barrier. Nothing that shows up on a routine endoscopy report, but not nothing either. If this strand holds, a mild anti-inflammatory acting locally in the gut lumen is a far more interesting proposition than it used to be.

Notice how badly acid suppression maps onto that list. Proton pump inhibitors reduce stomach acid. Three of those four faults have nothing directly to do with acid. That is why PPIs help some people with functional dyspepsia a great deal and do nothing whatsoever for others — and why a treatment working through a different set of mechanisms is worth testing rather than dismissing.

Back to Table of Contents

The 1989 Thai Trial

The foundational clinical study is Thamlikitkul and colleagues, published in the Journal of the Medical Association of Thailand in 1989. It is usually described in passing as "an old Thai study", which undersells it: it was a randomised, double-blind trial with both a placebo arm and an active comparator, run at a time when almost no herbal medicine anywhere was being tested that rigorously.

The design, in plain terms:

1. Patients with dyspepsia were randomly assigned to one of three treatments.
2. One group received Curcuma domestica capsules — turmeric rhizome powder — at 250 mg, four times daily.
3. One group received placebo capsules.
4. One group received a conventional antacid preparation, the standard of the day.
5. Treatment ran for seven days, and neither patients nor assessors knew who had received what.

The reported outcome favoured turmeric over placebo on dyspeptic symptom response. We are deliberately not quoting a response percentage here, because the exact figures are reported in a 1989 Thai journal that is not freely readable online, and a number recalled rather than read is a number that should not be on a health page. What can be said accurately is that the trial is consistently cited — in Thailand and in international herbal-medicine reviews — as the clinical basis for turmeric's standing as a dyspepsia remedy, and that its design was a genuine randomised double-blind comparison rather than an open observation.

Three things about that regimen are worth noticing, because they are still how the remedy is used:

• The dose is small. 250 mg of turmeric powder is a fraction of a teaspoon. Modern curcumin extract capsules often contain more curcuminoid than that entire capsule weighs.
• The frequency is high. Four times a day — with each meal and at bedtime. The remedy is timed to food, not to a clock.
• The course is short. Seven days. This was never conceived as something you take forever.

The trial's limitations are the limitations of its era: modest size by modern standards, a one-week horizon, symptom-based outcomes, and a single centre. It would not, on its own, convince a guideline committee in 2026. It did not have to be the only trial.

Back to Table of Contents

The 2023 Trial Against Omeprazole

In September 2023, Kongkam and colleagues published in BMJ Evidence-Based Medicine a randomised, double-blind trial of curcumin and a proton pump inhibitor in functional dyspepsia. This is the headline modern evidence for everything on this page, and it deserves to be understood properly rather than repeated as a slogan.

The design was three-arm, which is the single most important thing about it:

1. Curcumin alone
2. Omeprazole alone — the standard drug, one of the most widely prescribed medicines in the world
3. Curcumin plus omeprazole

Patients had functional dyspepsia, meaning structural disease had been excluded. The trial was run in Thailand, at Chulalongkorn, and it was double-blind with double-dummy placebos so that no one could tell from the pills which arm they were in. Symptoms were tracked with a validated dyspepsia severity score, with assessments over roughly a month.

The finding, stated as carefully as it deserves: all three arms improved, and the curcumin arm's improvement was comparable to the omeprazole arm's. Adding curcumin to omeprazole did not produce a clearly superior result over either alone. Curcumin was not shown to beat the drug; it was not shown to be beaten by it either.

Why that matters, and why it is easy to overstate:

• It matters because "comparable to omeprazole" is a high bar for any botanical. Omeprazole is not a soft comparator — it is the actual first-line therapy. Very few herbal trials are designed against the real standard of care rather than against placebo, and the ones that are usually lose.
• It is easy to overstate because a trial of this size cannot establish equivalence in the formal statistical sense. "No significant difference detected" is not the same as "proven equally effective"; it can also mean the trial was too small to detect a real difference. The authors were appropriately measured about this, and so should you be.
• It says nothing about anyone who has a diagnosed reason to be on a PPI. Erosive oesophagitis, Barrett's, a bleeding ulcer, long-term NSAID protection — these are structural indications and this trial did not study them. Nobody should stop a prescribed proton pump inhibitor on the strength of this paper.
• Safety signals were watched. Liver function was monitored, and the trial's safety reporting is part of why it appeared in a mainstream evidence-based medicine journal rather than a specialist herbal one.

Taken with the 1989 trial, the shape of the evidence is this: two randomised, double-blind, controlled trials, thirty-four years apart, in the same condition, run in the same country, both favouring turmeric. That is a small literature. It is also more than most of what sits on a supplement shelf can claim.

Back to Table of Contents

Why Poor Absorption Matters Less Here

Every serious discussion of turmeric runs into the same wall. Curcumin is absorbed badly. It is poorly soluble in water, it is chewed up rapidly by the liver and intestinal wall, and it is excreted quickly. Swallow a substantial dose and the concentration reaching your bloodstream is often barely detectable. This is why the famous 1998 piperine study exists — black pepper extract inhibits the enzymes that destroy curcumin, and co-administration raises blood levels dramatically — and why the modern supplement industry sells phospholipid complexes, nanoparticles and emulsions.

For a knee, a brain or a blood vessel, this is turmeric's central problem: the molecule has to travel to reach the target, and it mostly does not arrive.

Lopresti's 2018 review in Advances in Nutrition made the argument that inverts this for the gut, and it is the conceptual key to this entire leg. The curcumin that fails to be absorbed has not disappeared. It is in the gut. It remains in the lumen at concentrations orders of magnitude higher than the blood ever sees, in direct contact with the gastric and intestinal lining, and it travels intact into the colon, where it meets the microbiota. Lopresti's proposal was that curcumin's gastrointestinal actions — on the gut barrier, on local inflammation, on the microbiome, on gut-derived signalling that reaches the rest of the body — may account for a substantial share of its observed effects, rather than being a footnote to a failed delivery problem.

Two practical consequences follow, and both cut against supplement-shelf orthodoxy:

1. A cheap, plain preparation is defensible for a gut indication. If contact with the gut lining is the point, paying a premium to get curcumin out of the gut faster is at best beside the point.
2. The 1989 trial's small dose stops looking odd. 250 mg of rhizome powder four times daily delivers very little curcuminoid to the blood. It delivers a steady, meal-timed presence of turmeric in the stomach, which is a different thing and, for this indication, possibly the relevant one.

This remains a hypothesis, argued in a review, not a proven mechanism. But it is a hypothesis that predicts exactly the pattern the trial record shows — gut indications doing proportionally better than the pharmacokinetics would lead you to expect.

Back to Table of Contents

Breath Hydrogen: Measuring Gas Objectively

"Bloating" is a miserable thing to study, because it is a sensation and sensations cannot be measured with an instrument. Breath hydrogen is one of the few honest workarounds available.

Here is the logic. Human cells do not produce hydrogen gas. Every molecule of hydrogen in your breath came from bacteria fermenting carbohydrate somewhere in your gut; it diffuses into the blood, travels to the lungs and is exhaled. Measure breath hydrogen and you have an objective, non-invasive index of how much fermentation is going on — which is the physical substrate of a good deal of gas and distension.

Shimouchi and colleagues published a study in Digestive Diseases and Sciences in 2009 examining the effect of dietary turmeric on breath hydrogen in human subjects. It is a small study, and it should be read as a signal rather than a proof. Its value is that it looks at something measurable rather than at a symptom questionnaire, and it places turmeric's effect on intestinal gas production on a footing that does not depend on anyone's self-report.

What it does not do is establish a dose, a duration, or a clinical benefit. One small human study with an objective endpoint is a good reason to take a claim seriously and a bad reason to treat it as settled.

Back to Table of Contents

Gastric Emptying — The Mouse Evidence

This section comes with a label attached, and the label stays attached throughout: this is animal work. No human gastric emptying study has shown these effects, and anyone telling you turmeric has been proven to speed up a human stomach is going beyond the evidence.

Two mouse studies are worth knowing about because they propose a concrete mechanism rather than hand-waving about "digestive support".

The interstitial cells of Cajal

Your gut has a pacemaker. The interstitial cells of Cajal (ICC) sit in the gut wall between nerve endings and smooth muscle and generate the slow electrical waves that set the rhythm of contraction. Loss or dysfunction of these cells is implicated in gastroparesis and in several motility disorders. Lin and colleagues, publishing in Experimental and Therapeutic Medicine in 2021, reported that curcumin relieved gastric emptying dysfunction in mice — dysfunction induced experimentally with L-arginine and atropine — and traced the effect to the interstitial cells of Cajal.

That is a satisfying mechanism because it maps onto a real human pathology. It is still mice, and the dysfunction was chemically induced rather than spontaneous.

Functional gastrointestinal disorder models

Yu and colleagues, in the Journal of Medicinal Food in 2017, reported that curcumin alleviated functional gastrointestinal disorders in mice in vivo. Again: mice, experimental models, and a set of endpoints chosen by the investigators.

The right way to hold this evidence is as a plausible explanation waiting for a human test, not as a reason to expect your stomach to empty faster. If the ICC mechanism is real in people, it would neatly explain why the meal-related, fullness-and-early-satiety subtype of functional dyspepsia is where turmeric's traditional use has always been aimed. That is a hypothesis with a good pedigree and no human confirmation.

Back to Table of Contents

How People Actually Take It

Descriptive, not prescriptive — this is what the studies used and what the traditional regimen looks like.

1. Timing beats quantity. Both the traditional Thai regimen and the trial protocols tie doses to meals. Taking turmeric with food is not a stomach-protection afterthought here; it is the mechanism. Bile release, gastric contact and the motility question all happen around eating.
2. The traditional dose is modest and frequent. 250 mg of rhizome powder four times daily was the 1989 protocol — with each meal and at bedtime.
3. The modern extract dose is much higher in curcuminoid terms. Trials using standardised extracts deliver far more curcuminoid per day, divided across doses. Do not read a rhizome-powder milligram figure and an extract milligram figure as the same thing; they differ by more than an order of magnitude in curcuminoid content.
4. Two to four weeks is a fair trial. The 1989 study ran a week; the 2023 study ran about a month. If a month of consistent use has done nothing, the answer for you is no.
5. Stop if it burns. A minority of people get reflux, epigastric burning or loose stools from turmeric capsules. In a condition defined by upper-gut discomfort, a supplement that causes upper-gut discomfort has answered the question.
6. Food counts too. Nothing about this evidence requires a capsule. Turmeric used generously in cooking — the way it is used across South and Southeast Asia — is the oldest version of the intervention, it costs almost nothing, and the gallbladder and mucosal-contact mechanisms do not care whether the turmeric arrived in a capsule or a curry.

On piperine: black pepper extract raises curcumin blood levels substantially. For joint or systemic use that is the point. For a gut indication it is arguably counterproductive, and it also raises the odds of interfering with other medicines, because the same enzyme inhibition that spares curcumin spares other drugs too. If you take prescription medication, that is a conversation with a pharmacist.

Back to Table of Contents

The Honest Limits of This Evidence

If you read nothing else on this page, read this. The case for turmeric in functional dyspepsia is real and it is small.

1. Two trials is two trials. One from 1989, one from 2023. Both good designs. Neither large by the standards of drug development, where a licensing dossier runs to thousands of patients across many sites.
2. Both are from one country. Thailand's investigators deserve enormous credit for doing this work when nobody else would, and there is nothing improper about it — but replication in different populations, with different diets, different background rates of H. pylori and different expectations about herbal medicine, has not happened. Expectation matters in a symptom-defined condition.
3. The preparations differ. The 1989 trial used whole rhizome powder. Modern trials use standardised extracts. These are chemically different products and no trial has compared them for this indication. "Turmeric works for indigestion" hides the question of which turmeric.
4. Follow-up is short. One week and about one month. Functional dyspepsia is a relapsing condition measured in years. Nothing here tells you what happens at six months, or whether benefit persists, or what daily use for a decade does.
5. The placebo response in this condition is large. Trials of functional dyspepsia routinely see substantial improvement in the placebo arm. This is not a flaw in the patients; it is a property of symptom-defined conditions with fluctuating natural history. It is exactly why the 1989 trial's placebo arm and the 2023 trial's double-dummy design matter so much, and why the uncontrolled studies elsewhere in the turmeric literature prove so little.
6. Symptom scores are subjective endpoints. Legitimate and standard in this field — there is no blood test for dyspepsia — but softer than a tumour measurement or a survival curve.
7. Publication bias is unmeasurable here. With a literature this small, one or two unpublished negative trials would change the picture materially, and there is no way to know whether they exist.

The reasonable conclusion is not "turmeric is proven for indigestion" and not "there is no evidence". It is this: for meal-related upper-gut discomfort with no structural disease, turmeric is a low-cost, well-tolerated option with two randomised controlled trials behind it, a coherent set of mechanisms, and centuries of pharmacy-shelf use in a country that takes it seriously. Try it for a month, judge it honestly, and stop if it does nothing.

Back to Table of Contents

When to See a Doctor Instead

Functional dyspepsia is a diagnosis of exclusion. That phrase carries a real obligation: something has to have been excluded. The following are the standard alarm features, and any one of them means this article is not what you need.

• Unintentional weight loss — weight coming off without you trying
• Persistent vomiting, or vomiting blood, or vomit that looks like coffee grounds
• Black, tarry stools, or visible blood in the stool — black stools mean digested blood until proven otherwise
• Difficulty swallowing, pain on swallowing, or food that sticks
• Anaemia, or unexplained low iron on a blood test
• A palpable lump or mass in the abdomen
• New, persistent indigestion beginning after the age of 60 — new symptoms in an older adult are investigated, not treated blind
• A family history of stomach or oesophageal cancer
• Severe or escalating pain, especially pain that wakes you from sleep
• Jaundice — yellowing of the eyes or skin, dark urine, pale stools

There is also a specific point about acid-suppressing drugs. If you have been taking an over-the-counter proton pump inhibitor for weeks or months and it is the only thing keeping you comfortable, that is worth a proper assessment rather than a swap to a supplement. And if you are on a PPI because a doctor found something — an ulcer, erosive oesophagitis, Barrett's oesophagus, or protection alongside long-term anti-inflammatory drugs — nothing on this page applies to you. The 2023 trial studied functional dyspepsia specifically, meaning patients in whom those findings had been ruled out.

One more: Helicobacter pylori is a treatable bacterial cause of upper-gut symptoms and can be tested for with a breath test, a stool test or a biopsy. If you have persistent dyspepsia and have never been tested, ask. Curcumin is not an eradication therapy — a trial of a curcumin-based regimen failed to clear the organism, and we cover that failure in full on the IBS, Gut Inflammation and H. pylori article.

Back to Table of Contents

Key Research Papers

1. Kongkam P, Khongkha W, Lopimpisuth C, et al. (2023). Curcumin and proton pump inhibitors for functional dyspepsia: a randomised, double blind controlled trial. BMJ Evidence-Based Medicine. — PubMed PMID: 37696679 (the three-arm trial against omeprazole)
2. Thamlikitkul V, Bunyapraphatsara N, Dechatiwongse T, et al. (1989). Randomized double blind study of Curcuma domestica Val. for dyspepsia. Journal of the Medical Association of Thailand. — PubMed PMID: 2699615
3. Chamchoum E, Ghaleb J, Chamchoum N, et al. (2026). Functional Dyspepsia: An Updated Review of Pathophysiology, Epidemiology, Clinical Manifestations, and International Management Guidelines. Sage Open Pathology. — PubMed PMID: 42491169 (background on the condition itself)
4. Lopresti AL (2018). The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? Advances in Nutrition. — PubMed PMID: 29438458
5. Shimouchi A, Nose K, Takaoka M, et al. (2009). Effect of dietary turmeric on breath hydrogen. Digestive Diseases and Sciences. — PubMed PMID: 19034660
6. Lin P, Li B, Ye J, et al. (2021). Curcumin relieves mice gastric emptying dysfunction induced by L-arginine and atropine through interstitial cells of Cajal. Experimental and Therapeutic Medicine. — PubMed PMID: 33850520 (animal study, in mice)
7. Yu J, Xu WH, Sun W, et al. (2017). Curcumin Alleviates the Functional Gastrointestinal Disorders of Mice In Vivo. Journal of Medicinal Food. — PubMed PMID: 28880711 (animal study, in mice)
8. Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. — PubMed PMID: 9619120
9. Gupta SC, Patchva S, Aggarwal BB (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS Journal. — PubMed PMID: 23143785
10. Chainani-Wu N (2003). Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). Journal of Alternative and Complementary Medicine. — PubMed PMID: 12676044
11. Kwiecien S, Magierowski M, Majka J, et al. (2019). Curcumin: A Potent Protectant against Esophageal and Gastric Disorders. International Journal of Molecular Sciences. — PubMed PMID: 30909623
12. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. American Journal of Medicine. — PubMed PMID: 36252717

PubMed Topic Searches

1. PubMed: Curcumin and functional dyspepsia
2. PubMed: Functional dyspepsia and the Rome criteria
3. PubMed: Functional dyspepsia and gastric accommodation
4. PubMed: Duodenal eosinophils in functional dyspepsia
5. PubMed: Breath hydrogen and bloating
6. PubMed: Curcuma longa and dyspepsia, randomised trials
7. PubMed: Dyspepsia alarm features and endoscopy

Back to Table of Contents

Connections

• Turmeric for Digestive Health
• Ya Khamin Chan: Thai Traditional Use
• Turmeric, Bile and Fat Digestion
• Turmeric for IBS, Gut Inflammation and H. pylori
• Turmeric
• Turmeric Safety and Interactions
• Turmeric Bioavailability and Forms
• Turmeric Benefits
• History of Turmeric
• Fingerroot
• Javanese Turmeric
• Gut Health
• Culinary and Spice Herbs

Back to Table of Contents